TILT Biotherapeutics Oy

TILT Biotherapeutics Oy, based in Helsinki, Finland, specializes in innovative immunotherapies targeting solid tumors, particularly focusing on platinum-resistant ovarian cancer, utilizing advanced viral technology for cancer treatment. TILT Biotherapeutics Oy develops advanced immunotherapies for cancer treatment. Founded in 2013 in Helsinki, Finland, the company has engaged in a total of 9 deals. Its latest funding round occurred on May 13, 2025, where it raised USD 25.

6 mn in a Series B round led by European Innovation Council, Lifeline Ventures, Tesi, and Stephen Industries. The CEO, Akseli Hemminki, provides leadership to the company, contributing to its strategic direction. TILT Biotherapeutics (Tiltbio) specializes in the development of advanced immunotherapies targeting solid tumors, with a primary focus on platinum-resistant ovarian cancer. Their flagship product, TILT-123, is a cytokine-armed oncolytic adenovirus designed for intravenous delivery.

This innovative therapy uses modified viruses to infect and stimulate cancer cells, enhancing the immune system's recognition and attack on tumors. TILT-123 is currently undergoing Phase I/II clinical trials in both Europe and the United States, administered as a standalone treatment and in combination with other immunotherapies, such as immune checkpoint inhibitors and tumor-infiltrating lymphocyte therapy. The company targets a patient population with limited treatment options, specifically those who have not responded effectively to conventional treatments like surgery and chemotherapy. Their client base primarily includes healthcare providers, research institutions, and pharmaceutical partners interested in combination therapy data and the potential of oncolytic immunotherapy.

TILT Biotherapeutics generates revenue through partnerships and collaborations with pharmaceutical companies, focusing on the development and clinical evaluation of their investigational therapies. These collaborations involve shared costs and revenue from the commercialization of their therapies, providing a structured transaction framework based on mutual investment in clinical trials and research initiatives. The company reported a revenue of USD 3,935. 30 mn for the most recent year in 2023, with an EBITDA of USD -914,280.

60, indicating operational dynamics in their ongoing ventures. In May 2025, TILT Biotherapeutics Ltd raised USD 25. 6 mn in venture funding from returning investors such as European Innovation Council, Lifeline Ventures, Tesi, and Stephen Industries. This funding will be utilized to further develop the Phase 2 clinical trial of TILT-123, indicating the company's commitment to advancing its flagship product.

The company has plans for expanding its clinical trials geographically, focusing on both European and United States markets, aiming to establish a broader footprint in the immunotherapy field as they progress through clinical development.